CT-images in a 65-year-old male with bladdercarcinoma and lymph node metastasis (< 15 mm) in the right obturator region.
During treatment with immunotherapy the bladder lesion (target) and lymphadenopathy (non-target) completely disappeared.
This is a complete response.
CT images in a 58-year-old male with stadium 4 lung cancer, contralateral pulmonary, lymph node and osseous metastases, and previous treatment with lobectomy of the right lower lobe and chemoradiotherapy.
CT image on the right at response evaluation during treatment with immunotherapy shows complete disappearance of pulmonary metastases.
Does this mean CR?
Continue to the next images.
Although the lungmetastases have disappeared, other images showed unchanged sclerotic bone lesions and pleural effusion.
This makes it impossible to assign complete response, unless these lesions are proven not to be viable or malignant by FDG-PET or cytology.
CT images in a 63-year-old male with a melanoma and metastases of melanoma in the liver and inguinal lymph nodes.
There also was a renal angiomyelolipoma, which was a coincidental finding.
- Inguinal lymph node: 34 mm > 25 mm
- Liver lesion: 19 mm > 12 mm
- Liver lesion: 16 mm > 10 mm
- AML lesion: 19 mm > 25 mm
- AML lesion: 33 mm > 23 mm
- Other inguinal lymph nodes: regression
- Other liver lesions: regression
- Other AML lesions: regression.
Baseline SLD = 121
Follow-up SLD = 95
Percentage of decrease from baseline study is 21%, which means stable disease (SD).
CT images in a 71-year-old female with endometrial cancer with lung, lymph node and peritoneal metastases. Baseline images on the left and images at the first response evaluation during treatment with chemotherapy on the right.
- Lung lesion: 26 mm > 31 mm
- Lung lesion: 35 mm > 38 mm
- Lymph node carinal: 23 mm > 24 mm
- Peritoneal lesion: 31 mm > 37 mm
- Peritoneal lesion: 23 mm > 27 mm
- Other lung lesions: slightly increased
- Other mediastinal lymph nodes: slightly increased
- Other peritoneal lesion: slightly increased
Baseline SLD = 138
Follow-up SLD = 157
Percentage increase from baseline/nadir is 14%, which means that this is stable disease (SD).
CT images of a 66-year-old female with confluencing liver metastases of a mammacarcinoma.
Confluencing hepatic lesions, chosen as target and non target lesions, are stable or regress marginally during treatment with hormone therapy.
However, new peritoneal metastases appear with omental cake and ascites.
This means progressive disease.
CT images in a 59-year-old female with bone metastases of breast carcinoma during treatment with second line treatment with chemotherapy.
The bone metastases become more sclerotic during treatment, and if you look closely they were already present at the baseline examination.
The lesions do not change in size or number.
This sclerotic change of bone metastases represents a good response.